Journal article 296 views 89 downloads
Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial
Alison Birtle,
Mark Johnson,
John Chester,
Robert Jones,
David Dolling,
Richard T Bryan,
Christopher Harris,
Andrew Winterbottom,
Anthony Blacker,
James W F Catto,
Prabir Chakraborti,
Jenny L Donovan,
Paul Anthony Elliott,
Ann French,
Satinder Jagdev,
Benjamin Jenkins,
Francis Xavier Keeley,
Roger Kockelbergh,
Thomas Powles,
John Wagstaff,
Caroline Wilson,
Rachel Todd,
Rebecca Lewis,
Emma Hall
The Lancet, Volume: 395, Issue: 10232, Pages: 1268 - 1277
Swansea University Author: John Wagstaff
-
PDF | Version of Record
Released under the terms of a Creative Commons Attribution NonCommercial NoDerivs License (CC-BY-NC-ND).
Download (594.34KB)
DOI (Published version): 10.1016/s0140-6736(20)30415-3
Abstract
This paper reports the results of an open label phase III trial of Chemotherapy with platinum based chemotherapy versus observation in patients who had undergone nephrectomy for a transitional carcinoma of the upper urinary tract. Patients received four cycles of cisplatin/carboplatin at three weekl...
| Published in: | The Lancet |
|---|---|
| ISSN: | 0140-6736 |
| Published: |
Elsevier BV
2020
|
| Online Access: |
Check full text
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa53807 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| first_indexed |
2020-03-23T13:27:50Z |
|---|---|
| last_indexed |
2020-09-06T03:17:31Z |
| id |
cronfa53807 |
| recordtype |
SURis |
| fullrecord |
<?xml version="1.0"?><rfc1807><datestamp>2020-09-05T15:12:05.2974756</datestamp><bib-version>v2</bib-version><id>53807</id><entry>2020-03-10</entry><title>Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial</title><swanseaauthors><author><sid>fdab5e9e2fe06c93d3ffa19c816bdcf6</sid><firstname>John</firstname><surname>Wagstaff</surname><name>John Wagstaff</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2020-03-10</date><deptcode>SGMED</deptcode><abstract>This paper reports the results of an open label phase III trial of Chemotherapy with platinum based chemotherapy versus observation in patients who had undergone nephrectomy for a transitional carcinoma of the upper urinary tract. Patients received four cycles of cisplatin/carboplatin at three weekly intervals. 261 patients were randomised from 71 centres across the United Kingdom. At a median follow-up of 30.3 months chemotherapy significantly improved disease-free survival (hazard ratio 0·45, 95% CI 0·30–0·68; p=0·0001). Three year event free estimates were 71 and 46% for chemotherapy and observation respectively. 55 (43%) of patients given chemotherapy had grade 3 adverse events whilst 5 of 129 (4%) subjected to observation had grade 3 adverse events. Platinum based chemotherapy given within 90 days of nephrouretectomy significantly improved disease-free survival and should be offered to patients as a standard of care.</abstract><type>Journal Article</type><journal>The Lancet</journal><volume>395</volume><journalNumber>10232</journalNumber><paginationStart>1268</paginationStart><paginationEnd>1277</paginationEnd><publisher>Elsevier BV</publisher><issnPrint>0140-6736</issnPrint><keywords/><publishedDay>1</publishedDay><publishedMonth>4</publishedMonth><publishedYear>2020</publishedYear><publishedDate>2020-04-01</publishedDate><doi>10.1016/s0140-6736(20)30415-3</doi><url/><notes/><college>COLLEGE NANME</college><department>Medical School - School</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>SGMED</DepartmentCode><institution>Swansea University</institution><apcterm/><lastEdited>2020-09-05T15:12:05.2974756</lastEdited><Created>2020-03-10T17:08:30.3374077</Created><authors><author><firstname>Alison</firstname><surname>Birtle</surname><order>1</order></author><author><firstname>Mark</firstname><surname>Johnson</surname><order>2</order></author><author><firstname>John</firstname><surname>Chester</surname><order>3</order></author><author><firstname>Robert</firstname><surname>Jones</surname><order>4</order></author><author><firstname>David</firstname><surname>Dolling</surname><order>5</order></author><author><firstname>Richard T</firstname><surname>Bryan</surname><order>6</order></author><author><firstname>Christopher</firstname><surname>Harris</surname><order>7</order></author><author><firstname>Andrew</firstname><surname>Winterbottom</surname><order>8</order></author><author><firstname>Anthony</firstname><surname>Blacker</surname><order>9</order></author><author><firstname>James W F</firstname><surname>Catto</surname><order>10</order></author><author><firstname>Prabir</firstname><surname>Chakraborti</surname><order>11</order></author><author><firstname>Jenny L</firstname><surname>Donovan</surname><order>12</order></author><author><firstname>Paul Anthony</firstname><surname>Elliott</surname><order>13</order></author><author><firstname>Ann</firstname><surname>French</surname><order>14</order></author><author><firstname>Satinder</firstname><surname>Jagdev</surname><order>15</order></author><author><firstname>Benjamin</firstname><surname>Jenkins</surname><order>16</order></author><author><firstname>Francis Xavier</firstname><surname>Keeley</surname><order>17</order></author><author><firstname>Roger</firstname><surname>Kockelbergh</surname><order>18</order></author><author><firstname>Thomas</firstname><surname>Powles</surname><order>19</order></author><author><firstname>John</firstname><surname>Wagstaff</surname><order>20</order></author><author><firstname>Caroline</firstname><surname>Wilson</surname><order>21</order></author><author><firstname>Rachel</firstname><surname>Todd</surname><order>22</order></author><author><firstname>Rebecca</firstname><surname>Lewis</surname><order>23</order></author><author><firstname>Emma</firstname><surname>Hall</surname><order>24</order></author></authors><documents><document><filename>53807__16887__ffd8161242bd482e9fc27bbb7dd69583.pdf</filename><originalFilename>53807.pdf</originalFilename><uploaded>2020-03-23T10:21:18.6082428</uploaded><type>Output</type><contentLength>608607</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>Released under the terms of a Creative Commons Attribution NonCommercial NoDerivs License (CC-BY-NC-ND).</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>http://creativecommons.org/licenses/by-nc-nd/4.0/</licence></document></documents><OutputDurs/></rfc1807> |
| spelling |
2020-09-05T15:12:05.2974756 v2 53807 2020-03-10 Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial fdab5e9e2fe06c93d3ffa19c816bdcf6 John Wagstaff John Wagstaff true false 2020-03-10 SGMED This paper reports the results of an open label phase III trial of Chemotherapy with platinum based chemotherapy versus observation in patients who had undergone nephrectomy for a transitional carcinoma of the upper urinary tract. Patients received four cycles of cisplatin/carboplatin at three weekly intervals. 261 patients were randomised from 71 centres across the United Kingdom. At a median follow-up of 30.3 months chemotherapy significantly improved disease-free survival (hazard ratio 0·45, 95% CI 0·30–0·68; p=0·0001). Three year event free estimates were 71 and 46% for chemotherapy and observation respectively. 55 (43%) of patients given chemotherapy had grade 3 adverse events whilst 5 of 129 (4%) subjected to observation had grade 3 adverse events. Platinum based chemotherapy given within 90 days of nephrouretectomy significantly improved disease-free survival and should be offered to patients as a standard of care. Journal Article The Lancet 395 10232 1268 1277 Elsevier BV 0140-6736 1 4 2020 2020-04-01 10.1016/s0140-6736(20)30415-3 COLLEGE NANME Medical School - School COLLEGE CODE SGMED Swansea University 2020-09-05T15:12:05.2974756 2020-03-10T17:08:30.3374077 Alison Birtle 1 Mark Johnson 2 John Chester 3 Robert Jones 4 David Dolling 5 Richard T Bryan 6 Christopher Harris 7 Andrew Winterbottom 8 Anthony Blacker 9 James W F Catto 10 Prabir Chakraborti 11 Jenny L Donovan 12 Paul Anthony Elliott 13 Ann French 14 Satinder Jagdev 15 Benjamin Jenkins 16 Francis Xavier Keeley 17 Roger Kockelbergh 18 Thomas Powles 19 John Wagstaff 20 Caroline Wilson 21 Rachel Todd 22 Rebecca Lewis 23 Emma Hall 24 53807__16887__ffd8161242bd482e9fc27bbb7dd69583.pdf 53807.pdf 2020-03-23T10:21:18.6082428 Output 608607 application/pdf Version of Record true Released under the terms of a Creative Commons Attribution NonCommercial NoDerivs License (CC-BY-NC-ND). true eng http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| title |
Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial |
| spellingShingle |
Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial John Wagstaff |
| title_short |
Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial |
| title_full |
Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial |
| title_fullStr |
Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial |
| title_full_unstemmed |
Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial |
| title_sort |
Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial |
| author_id_str_mv |
fdab5e9e2fe06c93d3ffa19c816bdcf6 |
| author_id_fullname_str_mv |
fdab5e9e2fe06c93d3ffa19c816bdcf6_***_John Wagstaff |
| author |
John Wagstaff |
| author2 |
Alison Birtle Mark Johnson John Chester Robert Jones David Dolling Richard T Bryan Christopher Harris Andrew Winterbottom Anthony Blacker James W F Catto Prabir Chakraborti Jenny L Donovan Paul Anthony Elliott Ann French Satinder Jagdev Benjamin Jenkins Francis Xavier Keeley Roger Kockelbergh Thomas Powles John Wagstaff Caroline Wilson Rachel Todd Rebecca Lewis Emma Hall |
| format |
Journal article |
| container_title |
The Lancet |
| container_volume |
395 |
| container_issue |
10232 |
| container_start_page |
1268 |
| publishDate |
2020 |
| institution |
Swansea University |
| issn |
0140-6736 |
| doi_str_mv |
10.1016/s0140-6736(20)30415-3 |
| publisher |
Elsevier BV |
| document_store_str |
1 |
| active_str |
0 |
| description |
This paper reports the results of an open label phase III trial of Chemotherapy with platinum based chemotherapy versus observation in patients who had undergone nephrectomy for a transitional carcinoma of the upper urinary tract. Patients received four cycles of cisplatin/carboplatin at three weekly intervals. 261 patients were randomised from 71 centres across the United Kingdom. At a median follow-up of 30.3 months chemotherapy significantly improved disease-free survival (hazard ratio 0·45, 95% CI 0·30–0·68; p=0·0001). Three year event free estimates were 71 and 46% for chemotherapy and observation respectively. 55 (43%) of patients given chemotherapy had grade 3 adverse events whilst 5 of 129 (4%) subjected to observation had grade 3 adverse events. Platinum based chemotherapy given within 90 days of nephrouretectomy significantly improved disease-free survival and should be offered to patients as a standard of care. |
| published_date |
2020-04-01T04:06:57Z |
| _version_ |
1763753504335200256 |
| score |
11.016258 |